Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers

Louis S. Cristol, Ishwarlal Jialal, Scott M Grundy

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


The effect of 4 months of low-dose probucol treatment (250 mg/day) on LDL oxidation and on plasma-HDL cholesterol was studied in a prospective, double-blinded, randomized, placebo-controlled trial involving 26 male volunteers. LDL samples isolated at baseline and at 4 months were subjected to in vitro tests of LDL oxidation, involving copper-catalyzed, time-course experiments. For the placebo group, LDL oxidation did not significantly change over the 4-month period. However, in the probucol group, LDL oxidation was significantly inhibited at 4 months, as evidenced by assays measuring conjugated diene formation, lipid peroxide production and altered electrophoretic mobility of oxidized LDL. In fact, in the probucol group the 'lag-phase' of oxidation was prolonged 2.7-fold. Neither probucol nor placebo had a significant effect on plasma HDL-cholesterol: in the probucol group HDL-cholesterol fell from 37.7 ± 7.4 mg/dl to 34.2 ± 8.3 mg/dl (percentage decrease -8.9), while in the placebo group plasma HDL-cholesterol levels were 42.4 ± 8.3 mg/dl and 40.9 ± 7.0 mg/dl at baseline and 4 months (percentage decrease -2.7). Therefore, a low dose of probucol (250 mg/day) given daily seems to afford protection against the oxidative modification of LDL, and does not appear to exert any substantial effect on the plasma lipoprotein profile.

Original languageEnglish (US)
Pages (from-to)11-20
Number of pages10
Issue number1
StatePublished - Nov 1992

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers'. Together they form a unique fingerprint.

Cite this